<unk>  (Exanta® or Exarta®, H 376/95) is an anticoagulant that has been investigated extensively as a replacement for warfarin that would overcome the problematic dietary, drug interaction, and monitoring issues associated with warfarin therapy. In 2006, its manufacturer AstraZeneca announced that it would not attempt to market<unk>  after reports of hepatotoxicity (liver damage) during trials, and to discontinue its distribution in countries where the drug had been approved.
Ximelagatran
Otamixaban
Avatrombopag
Apixaban
Lusutrombopag
Enoxaparin
Reteplase
Dabigatran